In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
Readers can also check out part 1, part 2, part 3, part 4, and podcast 1 now.
Starting in January next year, the United States will welcome up to 10 adalimumab biosimilars referencing Humira, one of the most profitable drug in the world. Currently, there are several barriers to uptake to biosimilars, including payer and pharmacy benefit manager interference with formulary placement, misaligned incentives that favor prescribing the reference product over biosimilars, and reference manufacturer-led anti-competitive practices preventing biosimilar market entry. However, there are a number of policy and procedural efforts being put in place by congressional leaders, the FDA, and HHS the could help to boost biosimilar uptake and give adalimumab biosimilars a real chance to gain market share.
Today, I’m joined by Julie Reed, executive director of the Biosimilars Forum, a nonprofit organization aimed at the advancement of biosimilar adoption through collaboration with biosimilar manufacturers. Prior to her work with the Forum, she served as vice president and global corporate affairs lead of immunology, inflammation, and biosimilars at Pfizer and she is a staunch advocate for biosimilar adoption and the advancement of biosimilar legislation, including President Biden’s 2021 executive order on increasing competition in the pharmaceutical sector and the Biosimilars User Fee Amendment III, also known as BsUFA III. Our conversation today will focus on how federal policies could shape the adalimumab market next year and what congressional leaders can do now to help the process.
Show notes
This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars.
To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here.
To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here.
To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here.
To read part 4 of this series, "How Payers Can Prepare for Adalimumab Biosimilars," click here.
To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.